"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 4 | 6 |
| 2002 | 3 | 1 | 4 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 1 | 5 |
| 2007 | 1 | 4 | 5 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 2 | 3 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
-
Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis. Mov Disord Clin Pract. 2024 Oct; 11(10):1195-1202.
-
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024 Apr; 30(4):1096-1103.
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
-
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022 06; 22(6):489-498.
-
Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. Intern Med. 2022 Dec 15; 61(24):3719-3722.
-
Parkinson's disease and skin. Parkinsonism Relat Disord. 2021 01; 82:61-76.
-
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. J Neural Transm (Vienna). 2021 02; 128(2):273-277.
-
Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 08; 91(8):795-808.
-
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020 04 01; 38(10):1019-1029.